Here we report the establishment and characterization of a Prostate Cancer Patient Derived Explant (PCPDX) from a patient of West African ancestry with metastatic castration resistant disease. The following data represents gene expression in a series of mice carrying this PCPDX and undergoing different treatment courses.  Mice were treated for 10 weeks with either Enzalutamide, Cisplatin, or Docetaxel, or appropriate vehicle controls. SOURCE: Jennifer Freedman (jennifer.freedman@duke.edu) -  Duke Cancer Institute

Pluto Bioinformatics

GSE146402: Characterization of an Enzalutamide Resistant Primary Prostate Cancer Xenograft Derived from a Patient of West African Ancestry